Patents
In vitro growth of functional islets of Langerhans
Patent Number: 5834308This the success of the Edmonton Protocol for treating diabetes using allogeneic islets, the need for sources of islet cells has intensified. The patent addresses that need through teaching ways of growing and expanding islet cells from pancreatic stem cells.
Inventors: Peck, Ammon B. (Gainesville, FL); Cornelius, Janet G. (Gainesville, FL)
Assignee: University of Florida Research Foundation, Inc. (Gainesville, FL)
Date of First Priority Issue: Thursday April 28th, 1994
Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
Patent Number: 5834029This patent teaches ways of generating in vitro channels in which nerves can be grown. These channels can then be administered in vivo for the treatment of neurodegenerative diseases.
Inventors: Bellamkonda, Ravi (Boston, MA); Ranieri, John P. (Lausanne, CH); Aebischer, Patrick (Lutry, CH)
Assignee: CytoTherapeutics, Inc. (Lincoln, RI)
Date of First Priority Issue: Friday May 20th, 1994
Methods for making immunoisolatory implantable vehicles with a biocompatiable jacket and a biocompatible matrix core
Patent Number: 5834001This patent teaches ways of generating devices that contain cells or stem cells that can be implanted without fear of immune mediated rejection.
Inventors: Dionne, Keith E. (Rehoboth, MA); Emerich, Dwaine F. (Providence, RI); Hoffman, Diane (Cambridge, MA); Sanberg, Paul R. (Spring Hill, FL); Christenson, Lisa (New Haven, CT); Hegre, Orion D. (Green Valley, AZ); Sharp, David W. (St. Louis, MO); Lacy, Paul E.
Assignee: Brown University Research Foundation
Date of First Priority Issue: Thursday April 25th, 1991
Methods and compositions of growth control for cells encapsulated within bioartificial organs
Patent Number: 5833979Lets imagine that one wanted to implant embryonic stem cells into a human. The first concern would be rejection by allogeneic immunity. To overcome this one could immune suppress, which is not desirable, or one could encapsulate the cells. If the cells are encapsulated but start proliferating, then they can either die or break through the encapsulation device. This patent teaches the use of UV...
Inventors: Schinstine, Malcolm (Ben Salem, PA); Shoichet, Molly S. (Toronto, CA); Gentile, Frank T. (Warwick, RI); Hammang, Joseph P. (Barrington, RI); Holland, Laura M. (Horsham, PA); Cain, Brian M. (Everett, MA); Doherty, Edward J. (Mansfield, MA); Winn, Shelley R
Assignee: CytoTherapeutics, Inc. (Lincoln, RI)
Date of First Priority Issue: Wednesday July 20th, 1994
Method for recombinant production of human pluripotent granulocyte colony-stimulating factor
Patent Number: 5830705This is a patent on ways of generating a cytokine called human p-G-CSF. I wonder what the modern name of this cytokine is? In any case, the invention teaches that this cytokine stimulates hematopoietic stem cells proliferation.
Inventor: Souza, Lawrence M. (Witherspoon, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Friday August 23rd, 1985
Method of detecting hematopoietic progenitor cells
Patent Number: 5830701This patent provides devices that can quantify hematopoietic stem cell numbers from a pool of cells through non-immunological means.
Inventors: Houwen, Berend (Redlands, CA); Tsujino, Yukio (Hyogo-ken, JP); Morikawa, Takashi (Hyogo-ken, JP); Ikeuchi, Yoshiro (Hyogo-ken, JP); Hamaguchi, Yukio (Hyogo-ken, JP)
Assignee: Tao Medical Electronics Co., Ltd. (JP)
Date of First Priority Issue: Friday March 28th, 1997
Human oligodendroglial progenitor cell line
Patent Number: 5830651This patent covers a neural stem cell line that can differentiate into neurons, oligodendrocytes, and glial cells. This cell line can be used for drug discovery since it provides a uniform cellular population. These cells may be purchased by the public from ATCC.
Inventors: Cauley, Keith (Burlington, VT); Kukekov, Valery (San Diego, CA)
Assignee: Signal Pharmaceuticals, Inc. (San Diego, CA)
Date of First Priority Issue: Monday May 1st, 1995
Method of selecting pluripotent hematopioetic progenitor cells
Patent Number: 5827742This patent takes advantage of the fact that early hematopoietic stem cells are usually CD34+ and quiescent. By treatment of CD34+ cells with cytotoxic agents that kill proliferating cells, a population of primitive stem cells may be obtained.
Inventor: Scadden, David T. (Weston, MA)
Assignee: Beth Israel Deaconess Medical Center, Inc. (Boston, MA)
Date of First Priority Issue: Thursday September 1st, 1994
Adipogenic differentiation of human mesenchymal stem cells
Patent Number: 5827740Treatment of mesenchymal stem cells with a glucocorticoid together with an agent that increases intracellular cAMP is disclosed as one of several methods for inducing the differentiation of mesenchymal stem cells into adipocytes.
Inventor: Pittenger, Mark F. (Severna Park, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Tuesday July 30th, 1996
Pluripotent mesenchymal stem cells and methods of use thereof
Patent Number: 5827735This patent provides a new type of stem cell that is similar to the mesenchymal stem cells covered by Osiris. It appears that the stem cells disclosed in this patent are derived from muscle cells. If these cells are mesenchymal or express the markers SH2-4 covered by Osiris, this could be an interesting patent to watch out for.
Inventors: Young, Henry E. (Macon, GA); Lucas, Paul A. (Poughkeepsie, NY)
Assignee: MorphoGen Pharmaceuticals, Inc. (New York, NY)
Date of First Priority Issue: Monday June 22nd, 1992